Background: In premenopausal women with hormone receptor-positive breast cancer (BC), 5 years of tamoxifen is recommended. Little is known about reasons for interruption in this population. The aim was to estimate the incidence of tamoxifen interruption and its correlates among younger women.
introduction
Breast cancer (BC) is the most frequently diagnosed cancer in women in Western countries. During the last decade, the mortality rate from BC has declined, largely as a result of more widespread application of chemotherapy and adjuvant endocrine therapy (AET) [1] . The latter has been shown to improve overall and relapse-free survival in women with hormone receptor-positive BC [2] . In those who are premenopausal at the time of BC diagnosis, the recommended adjuvant therapy is 5 years of tamoxifen [3] . As with any therapy, high adherence to treatment (i.e. respecting the prescription in terms of timing, dosage, and frequency [4] ) and persistence (continuation of treatment of the prescribed length of time [4] ) are needed to obtain an optimal clinical outcome. The survival benefit from tamoxifen increases with increased treatment duration [5] , and a cohort study has shown that women who interrupted tamoxifen before the completion of 5 years had increased risk of death [6] . However, despite great variability in methods used, reported rates of nonpersistence are consistently high, varying from 19% to 33% at 3 years [7] [8] [9] after treatment initiation and reaching 50% at 5 years [6, 9] . Most data available regarding persistence to AET are from studies including only older women with BC [10, 11] . Although some studies have shown that younger women with BC are at higher risk of AET interruption [7, 12] , little is known about the reasons for interruption in this population.
The aim of this prospective study, combining patient interviews, medical questionnaires, and AET prescription refill data, was to estimate the incidence of first AET interruption and its determinants in a French representative sample of women with BC, aged £40.
materials and methods

data source
The cohort Elippse 40 was implemented in Southeastern France to document consequences of BC and its treatments on women's daily and social lives, quality of life, and survival. There are 5 million inhabitants in the study area. Eligible patients for enrollment in the Elippse 40 cohort were all women with biopsy-proven primary BC, aged 18-40, living in Southeastern France, and registered since September 2005 by the French National Health Insurance Fund (NHIF) in the long duration disease registry. The NHIF includes the four major health insurance schemes (for salaried workers, farmers, professional soldiers, and self-employed workers) that cover 98% of the French population. Patient selection was conducted with the collaboration of the NHIF advisory physicians. Women with distant metastasis at diagnosis, serious cognitive troubles, acute psychiatric disease, and those unable to answer a questionnaire were excluded. Patient interviews were conducted by trained personnel. The study was approved by the French National Committee on Informatics and Freedom (CNIL).
patient data
Eligible patients from Elippse 40 were asked to answer a short, mailed selfadministered questionnaire at enrollment and asked to participate in computer-assisted telephone interviews [13] at 10, 16, and 28 months after BC diagnosis. The self-administered questionnaire included questions about patient's sociodemographic characteristics, circumstances of diagnosis, and its announcement. The phone interviews detailed sociodemographic characteristics, treatments and side-effects, patientprovider relationships (including information about AET and patient participation in the decision to start treatment), medical follow-up, fear of relapse, illness experience, and familial and social support. Psychometric scales were used to measure quality of life (WHOQOL-BREF [14] ) and depressive symptoms (CES-D [15] ) at all follow-up interviews.
In this study, two scores were computed using self-reported symptoms associated with tamoxifen: a specific menopausal symptoms score including hot flushes, dyspareunia, menstrual disorders, and fluid retention; and a score of nonspecific menopausal symptoms including fatigue and/or insomnia, distress and/or nervousness, digestive disorders, and visual problems. Adverse events associated with surgery or radiotherapy included lymphedema, loss of function of one's arms, thoracic pain, burning pain, and surgical or radiotherapy scars. Questions about symptoms were asked in such a way as to avoid any implied association with the treatment received.
medical records
In parallel with each patient interview, a medical record was collected from the patient's physician. The first medical questionnaire (10 months after diagnosis) dealt with the patient's medical history, concurrent diseases (including comorbidities of the Charlson index [16] ), pathological assessment of BC, and treatment modalities, together with family history of breast and/or ovarian cancer. The subsequent medical questionnaires (at 16 and 28 months after diagnosis) collected information about the current treatments, pathological events, relapse, and metastasis.
pharmacy refill data
Data on dispensed AET [tamoxifen and aromatase inhibitors (AIs)] were collected every 6 months, using the NHIF drug delivery database. This database exhaustively records all filled prescriptions, the data about each delivery being electronically sent by the pharmacy to the NHIF. The dates and dosages of AET deliveries, together with the number of days supplied, were available for all eligible women in the study, but only anonymously for those who refused to participate. In France, AET is free of charge and is dispensed monthly even though the prescription may cover up to 3 months. Data on filled prescriptions for psychotropic drugs (antidepressants, hypnotics, and sedatives) were also available for all women eligible to enter the Elippse 40 cohort.
sample selection
Among women diagnosed with BC between September 2005 and July 2008 and included in the Elippse 40 cohort, we restricted our study sample to those with hormone receptor-positive invasive BC (estrogen and/or progesterone receptors) who were alive and experienced no BC recurrence during the study period, and therefore who were recommended tamoxifen [17] [18] [19] .
outcomes
Interruption of tamoxifen was defined as two or more consecutive months of tamoxifen interruption, based on pharmacy refill [9] . Assuming that reasons for interruption may vary over time, tamoxifen interruptions were studied in two separate short time intervals: first during the period from tamoxifen initiation until 16 months after BC diagnosis (corresponding to a 2-month interruption over the first months of treatment); and second during the period from 16 to 28 months after BC diagnosis (2-month interruption over 12 months). Interruptions occurring during the first and the second periods were defined as 'early interruptions' and 'late interruptions', respectively. Women who had an early interruption but who restarted tamoxifen before the 16th month interview were also included in the late interruption analysis.
statistical analysis
The association between outcomes and explanatory variables was evaluated using logistic regression. All variables whose critical probability 'P' was <0.20 in univariate analyses were eligible for the multivariate model. The final multivariate model was built using a backward approach based on the log likelihood ratio test (P < 0.05). Sensitivity analyses for both the first and second periods outlined above were carried out on the extended dataset using a Cox proportional hazards model. Both analyses included women initially excluded due to cancer recurrence and those who switched to AIs during the study period. The latter were censored at the date of cancer recurrence (when the specific date was not indicated in the questionnaire detailing recurrence, the date halfway between that questionnaire and the previous one was chosen) and date of switching. Statistical analyses were carried our using SAS 9.1.3 software (SAS Institute, Inc., Cary, NC).
results
A total of 218 women diagnosed between September 2005 and July 2008 had hormone receptor-positive invasive BC. Among them, 9 women had BC recurrence, 2 died during the study period, 10 did not participate in the 16th month interview, and 1 had insufficient medical data. Accordingly, 196 women were analyzed ( Figure 1 ).
baseline characteristics
Mean age at diagnosis of these 196 women was 37 years [standard deviation (SD) = 3.5], and 39% had not completed secondary school education. A majority were living in a couple (85%) and 84% had at least one child. Moreover, 7% had severe comorbidities and 35% had a family history of breast or ovarian cancer.
Regarding BC characteristics, 33%, 51%, and 15% had stage 1, stage 2, and stage 3 cancer, respectively. Initial BC stage was unknown for two women who received neoadjuvant chemotherapy. One-third (32%) of our sample had grade 3 tumors, 53% had grade 2, and 14% had grade 1; tumor grade was unknown for three women. All studied women had had surgery, 62% having had breast-conserving surgery. A large majority had received chemotherapy (88%) and radiotherapy (95%). One-third (33%) had received gonadotropin-releasing hormone.
AET treatments
Among the 196 women, 7% (n = 13) did not initiate AET. Although these latter tended to be younger and to have a lower BC stage than those who initiated AET, the difference was not significant. Eighty-four percent of the women, who had been treated with surgery, chemotherapy, and radiation, started AET on average 9.0 months after BC diagnosis [interquartile range (IQR) = 7.1-10.0], and the remaining 16%, treated with fewer treatment modalities, started AET on an average of 5.0 months after BC diagnosis (IQR = 4.0-7.0). Tamoxifen was prescribed in 93% of cases (n = 171) and AIs in 7% (n = 12). Ten women switched their treatment from tamoxifen to AIs during the study period.
AET interruption
After excluding 10 women who switched treatments, tamoxifen interruption was analyzed among the remaining 161 women. During the whole study period, 42% of the women (n = 67) interrupted their tamoxifen treatment. Moreover, among these latter, 40% (n = 27) did not restart any AET during the study period. The median duration from tamoxifen initiation to interruption was 10.7 months (IQR = 4.0-16.0).
Among women eligible from the entire NHIF database but not included in the Ellipse 40 cohort, the rate of tamoxifen interruption was similar. Among the 12 women treated with AIs, 42% interrupted their treatment during the study period (i.e. two or more consecutive months without dispensed prescription of any AET).
early interruption of tamoxifen
During the period between tamoxifen initiation and the 16th month after BC diagnosis, 21 women (13%) interrupted tamoxifen. Table 1 shows the factors associated with early interruption. No association was found between interruption and age, income, family life, tumor characteristics, type of initial treatment and related side-effects, quality of life, specialty of the physicians who provided follow-up, CES-D score or consumption of psychotropic drugs. In multivariate analyses, after adjusting for the delay between diagnosis and tamoxifen initiation, early interruptions were more frequent among women with less social support and those who considered that information they received about tamoxifen was not understandable.
late interruption of tamoxifen
Excluding the 7 women who had early tamoxifen interruption and did not restart this treatment, 52 (34%) other women interrupted tamoxifen treatment. Table 2 describes specific and nonspecific menopausal symptoms reported by women treated with tamoxifen 16 months after BC diagnosis. Among the 154 women who had not interrupted their treatments, 86% and 77% reported at least one specific and at least one nonspecific menopausal symptom, respectively. Suffering from fluid retention was strongly associated with tamoxifen interruption during the following year [OR = 2.3 (95% confidence interval 1.1-4.5), P = 0.02]. Table 3 shows factors associated with late interruption of tamoxifen. In multivariate analysis, the following factors remained significantly associated with the outcome: poor social support, no longer fearing cancer relapse, two or fewer treatment modalities, no opportunity to ask questions at the time of diagnosis, and reporting more than two specific menopausal symptoms.
Both sensitivity analyses (which included those women initially excluded due to cancer recurrence, switching, or not having participated in the 16th month interview) confirmed the pattern of factors associated with early and late interruptions. The only exception was for the late interruption analysis, where the reduction in fear of cancer relapse was still inversely associated with interruption but no longer significant.
discussion
In this population of younger women with nonmetastatic BC who were recommended to receive tamoxifen, we found that more than one in five either did not initiate AET or definitively stopped taking it in the months following their first prescription. Moreover, 42% had had at least two consecutive months of AET interruption within the first 2 years of treatment. 
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Our results are consistent with other studies, which have shown that younger age was associated with low AET adherence and low persistence in women with BC [7, 12, 20] . Barron et al. [7] and Hershman et al. [12] reported an interruption that was ‡6 months for 22% of their study populations 1 year after starting AET.
Another important result of our study is to highlight factors associated with AET interruption among younger women with BC and to show that these factors differ according to the period considered. It is interesting to note that the quality of treatment-related information provided by health providers has a strong impact on persistence during the first months of treatment. Poor initial patient-provider relationship and the difficulty patients had asking questions had a negative impact on persistence to treatment later on. The informational needs of women taking AET are not always met. In a recent European survey on patient knowledge about AET, only 26% of women with BC received information about the risk of their cancer recurring and 15% about the possible long-term effects of the treatments [21] . However, patient beliefs about prescribed medicine are known to be important predictors of adherence [22] . A negative perception of risks and benefits of tamoxifen therapy has been shown to be associated with interruption in older women with BC [8, 23] , and with low adherence in 35-to 65-year-old women [24] . Conversely, in one web-based survey [25] , knowing that adherence can improve one's clinical outcome was the main factor cited by women for increased adherence to oral medications. Furthermore, modest gains in survival seem to be a sufficient reason to make AET worthwhile for premenopausal women with early-stage BC [26] . In our study sample, the reduction of fear of relapse was inversely associated with AET interruption. This appears to be consistent with poor knowledge about the risk of BC recurrence and the lack of information about the positive effects of AET on reducing recurrence. Women need more information about their disease, its treatment, and their risk of relapse.
Social support is known to improve adherence to medical treatment in general [27] and also to oral-based cancer treatment [28] . In our survey, the number of family members or friends supporting the patient was associated with persistence at the very beginning of treatment and also Annals of Oncology original articles later on. In the context of other diseases like human immunodeficiency virus or hepatitis C whose treatments are particularly burdensome for patients in terms of major sideeffects, the role of family members in providing support for long-term adherence has been clearly demonstrated [29, 30] . Health care providers should also include close family members when providing information about AET, in order to improve their understanding of the medication, its longterm role, and associated side-effects, thereby contributing to improving patient persistence. It is known that adverse effects are a major reason for tamoxifen interruption, particularly during the first years of treatment [9, 31, 32] . According to our results, perceived symptoms that heavily impacted persistence in younger women were specific menopausal symptoms, particularly fluid retention. Menopausal symptoms may be especially worrying for this age-group; they are perceived as signs of aging and an attack on femininity [33] . A previous study has shown that a lack of information about side-effects decreases persistence [32] . Thus, physicians should inform women of possible side-effects and manage them as effectively as possible. Nevertheless, randomized trials [34, 35] found no significant difference between fluid retention in tamoxifen and placebo-treated patients. This suggests that patients and/ or doctors may inaccurately assume that this symptom is related to tamoxifen. Consequently, educating patients about this fact would seem pertinent.
On the contrary, we found no association between persistence to AET and depression, which is usually considered a predictor of poor persistence to medical treatment, irrespective of type [10, 36] . Similarly, and unlike other studies, we did not find any relationship between AET persistence and use of psychotropic drugs [7] , or financial issues [25, 36, 37] . In our survey, low income was not a factor of nonpersistence as AET, like all prescribed medications, is free of charge for patients with BC in the French health care system.
An advantage of this study is that, unlike most others carried out to date, the 7% of women who did not initiate the recommended AET in our study were identified. Although treatment refusal was not systematically recorded, these women were hormone receptor-positive, recommended to receive tamoxifen and had no contraindication identified in their medical records. Given these facts, it is likely that most of them refused treatment. To our knowledge, the only other published data on this topic reported rates of treatment noninitiation from 9% to 30%, the latter being reported among women with BC with low income [38, 39] . Treatment refusals and associated reasons are important to consider, as this population is at higher risk of cancer relapse than their postmenopausal counterparts; further investigations need to be carried out. Three limitations to our study need to be mentioned. First, although there is no gold standard method to measure treatment persistence [36, 40] , prescription refill is usually considered as a valuable method [41] . Although it overestimates the real intake of the medication, it probably does not affect the association between persistence and its predictors. Nevertheless, the rates of nonpersistence observed were particularly high. Second, the size of our sample was limited to study-specific subgroups, such as women who refused treatment. Conversely, one of the original aspects of our survey is the description of women who definitely discontinued their AET or who simply interrupted for a limited period of time. Third, no association was found between tamoxifen nonpersistence and being childless, whereas desire for further pregnancy may have been a reason to refuse or to discontinue treatment, as previously shown in a qualitative survey [33] . More detailed data about family planning were not available. Further analysis including data about family planning needs to be carried out.
Although previous studies have been based on databases limited to specific patient populations [9, 11, 39] it is worth underlining that our study population is a representative sample of younger women with BC in the general population, as the NHIF provides universal health coverage. Our specific sample corresponds to 75% of all BC cases in younger women throughout the geographical area covered by our study. Moreover, as data were available for the remaining 25%, we were able to verify that their tamoxifen interruption rates were comparable, thereby enabling the persistence behavior of younger BC population to be estimated in a real-world setting.
Improving persistence to adjuvant cancer therapy in premenopausal women is an important challenge for oncologists and other health care workers. They must take more time to explain the role of adjuvant therapy, to describe its possible side-effects, and to emphasize its importance. Although the prescribing physician is likely to be the first person to explain the treatment, nurses and other health care professionals can deliver repeated information during followup. Improved management about side-effects is probably needed. Moreover, health care workers must be alert to finding those patients who are socially excluded, in order to give them more support in the first months after AET initiation.
